FDA-cleared profile

SIGNA Artist

GE Healthcare (Tianjin) Company Limited · MRI · FDA-cleared (510(k))

Authorized purpose: SIGNA Artist is a 1.5T whole-body MRI system; K202238 adds AIR Recon DL reconstruction to reduce noise and ringing and support improved image quality or shorter acquisitions.

Clinical role
Whole-body MR acquisition and reconstruction with optional AIR Recon DL image reconstruction.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: Depending on the region of interest being imaged, contrast agents may be used. The addition of the AIR Recon DL feature does not impact the intended use of the SIGNA Artist system.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: SIGNA Artist is a 1.5T whole-body MRI system; K202238 adds AIR Recon DL reconstruction to reduce noise and ringing and support improved image quality or shorter acquisitions.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: The system uses a combination of time varying magnetic fields (gradients) and RF transmissions to obtain information regarding the density and position of elements exhibiting magnetic resonance.
  • Who uses it?Intended users: Operators of the system and trained physicians interpreting the images and/or spectra.
  • What does the software produce?Output: Diagnostic MR images, spectra, and derived parameters, including AIR Recon DL reconstructions where enabled.
  • What is its most important limitation?Key limitation: Depending on the region of interest being imaged, contrast agents may be used. The addition of the AIR Recon DL feature does not impact the intended use of the SIGNA Artist system.

Clinical takeaway. Clinical role: SIGNA Artist is a 1.5T whole-body MRI system; K202238 adds AIR Recon DL reconstruction to reduce noise and ringing and support improved image quality or shorter acquisitions.

Evidence takeaway. Evidence from the reviewed source record: K202238 describes manufacturer AIR Recon DL reconstruction and system testing. Public family materials support current implementation context; reviewed recalls cover missing slices, cryogen venting, orientation, table caster locks, and Low-SAR B1+RMS behavior rather than a single common AI failure mode.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
SIGNA Artist is a 1.5T whole-body MRI system; K202238 adds AIR Recon DL reconstruction to reduce noise and ringing and support improved image quality or shorter acquisitions.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Whole-body MR acquisition and reconstruction with optional AIR Recon DL image reconstruction.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
The system uses a combination of time varying magnetic fields (gradients) and RF transmissions to obtain information regarding the density and position of elements exhibiting magnetic resonance.
  • Exact FDA submission
  • Checked 2026-09-19

This is the exact acquisition description; the dossier's supported-coil, sequence, and protocol inventory is not stated in this packet as an input requirement.

Output and clinician action
Diagnostic MR images, spectra, and derived parameters, including AIR Recon DL reconstructions where enabled.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Hospital and outpatient diagnostic MRI departments.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Operators of the system and trained physicians interpreting the images and/or spectra.
  • Exact FDA submission
  • Checked 2026-09-19

The packet identifies operators and trained-physician interpretation but does not establish the dossier's MR-technologist role label.

Limitations
Depending on the region of interest being imaged, contrast agents may be used. The addition of the AIR Recon DL feature does not impact the intended use of the SIGNA Artist system.
  • Exact FDA submission
  • Checked 2026-09-19

These are the packet's direct labeled-use boundaries; the recalled-device and generalized performance language is not retained.

Evidence summary
K202238 describes manufacturer AIR Recon DL reconstruction and system testing. Public family materials support current implementation context; reviewed recalls cover missing slices, cryogen venting, orientation, table caster locks, and Low-SAR B1+RMS behavior rather than a single common AI failure mode.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K202238 describes manufacturer AIR Recon DL reconstruction and system testing. Public family materials support current implementation context; reviewed recalls cover missing slices, cryogen venting, orientation, table caster locks, and Low-SAR B1+RMS behavior rather than a single common AI failure mode.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K202238 FDA performance package for SIGNA Artist

  • DesignManufacturer MR system, image-quality, reconstruction, software, safety, and AIR Recon DL verification
  • PopulationRepresentative whole-body MRI acquisitions and AIR Recon DL reconstruction workflows
  • Scopeexact submission
  • Tested versionSIGNA Artist release cleared in K202238
  • IndependenceSponsor or vendor study

K202238

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
5 reviewed FDA recall records in the 2026-09-02 openFDA snapshot natively identify K202238. Read the model- and version-scoped events and confirm affected-unit and correction status with the manufacturer. FDA recall Z-0139-2022 affected SIGNA Artist because some slices could be missing and leave a gap of anatomy in three-dimensional volume images. FDA lists the recall as terminated. FDA recall Z-0600-2022 includes superconducting magnets used in SIGNA Artist systems whose cryogen ventilation might not meet venting requirements. FDA lists the recall as open and classified. FDA recall Z-2061-2021 affected SIGNA Artist because an unintended patient-orientation change before the initial localizer could produce incorrectly annotated or flipped images. FDA lists the recall as open and classified. FDA recall Z-2299-2025 includes SIGNA Artist patient tables because planned maintenance might omit checks of caster-lock function, allowing movement during patient transfer. FDA lists the recall as open and classified. FDA recall Z-2469-2024 includes SIGNA Artist software DV26.0 through MR30.1 because predicted B1+RMS could exceed the prescribed Low SAR limit for specified FLAIR configurations and overheat an MR-conditional implant. FDA lists the recall as open and classified.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-0139-2022

Terminated

2021-10-16

Exact SIGNA Artist model match. This is an image-completeness issue; confirm the installed correction and retain local checks for missing anatomy.

recall: Z-0600-2022

Open, Classified

2021-12-23

Exact system-family match. This is a magnet-room and cryogen-venting issue, not an AIR Recon DL algorithm defect; confirm affected magnet and ventilation inspection status.

recall: Z-2061-2021

Open, Classified

2021-07-12

Exact SIGNA Artist model match. Verify the correction and ensure the prescribed orientation is checked against actual patient position before scanning.

recall: Z-2299-2025

Open, Classified

2025-08-13

Exact system-model match. This is a patient-table maintenance issue, not an AIR Recon DL algorithm defect; confirm inspection and corrective-action status.

recall: Z-2469-2024

Open, Classified

2024-08-02

Exact model and affected software-version match. Confirm installed software, the prescribed workaround or correction, and implant scanning controls.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: The system uses a combination of time varying magnetic fields (gradients) and RF transmissions to obtain information regarding the density and position of elements exhibiting magnetic resonance.

    Scope: Exact FDA submission. This is the exact acquisition description; the dossier's supported-coil, sequence, and protocol inventory is not stated in this packet as an input requirement.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K202238: SIGNA Artist

  2. Routing

    Source context, not route validation: DICOM MR workflow with model- and release-specific network objects; validate PACS, RIS, worklist, scaling, orientation, and advanced image compatibility.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K202238: SIGNA Artist · SIGNA Artist 1.5T wide-bore MRI system · GE HealthCare AIR Recon DL

  3. AI processing

    Source context, not route validation: Installed 1.5T wide-bore MR system with compatible AIR Recon DL software and reconstruction hardware.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K202238: SIGNA Artist · SIGNA Artist 1.5T wide-bore MRI system · GE HealthCare AIR Recon DL

  4. Returned objects

    Source context, not route validation: Diagnostic MR images, spectra, and derived parameters, including AIR Recon DL reconstructions where enabled.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K202238: SIGNA Artist

  5. Viewer/worklist/report

    Unresolved route: Diagnostic MR images, spectra, and derived parameters, including AIR Recon DL reconstructions where enabled.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K202238: SIGNA Artist

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed 1.5T wide-bore MR system with compatible AIR Recon DL software and reconstruction hardware.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM MR workflow with model- and release-specific network objects; validate PACS, RIS, worklist, scaling, orientation, and advanced image compatibility.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only mr technologists and trained operators, with images and spectra interpreted by trained physicians. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: AIR Recon DL performance depends on sequence, anatomy, protocol, and installed software. Exact affected units and correction status must be checked for the five reviewed SIGNA Artist recalls.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K202238 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM MR workflow with model- and release-specific network objects; validate PACS, RIS, worklist, scaling, orientation, and advanced image compatibility.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AIR Recon DL performance depends on sequence, anatomy, protocol, and installed software. Exact affected units and correction status must be checked for the five reviewed SIGNA Artist recalls.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: AIR Recon DL performance depends on sequence, anatomy, protocol, and installed software. Exact affected units and correction status must be checked for the five reviewed SIGNA Artist recalls.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K202238
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-09-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 5 FDA recall candidates were manually reviewed: 5 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 5 postmarket candidate records; 5 have been reviewed (5 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

13 sources - 3 history items

Source ledger

  1. FDA K202238: SIGNA Artist

    U.S. Food and Drug Administration - Published 2020-09-04 - Accessed 2026-09-19

    Scope: modality, anatomy, output, purpose, intendedUsers, input, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-0139-2022: SIGNA Artist nuclear magnetic resonance imaging system

    U.S. Food and Drug Administration - Published 2021-10-16 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. FDA recall Z-0600-2022: GE Healthcare MR superconducting magnets, a component of GE Healthcare SIGNA Artist system, nuclear magnetic resonance imaging system.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. FDA recall Z-2061-2021: SIGNA Artist, Nuclear Magnetic Resonance Imaging System

    U.S. Food and Drug Administration - Published 2021-07-12 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  6. FDA recall Z-2299-2025: GE Signa Artist, Nuclear Magnetic Resonance Imaging System

    U.S. Food and Drug Administration - Published 2025-08-13 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  7. FDA recall Z-2469-2024: SIGNA Artist, with affected software versions: DV26.0, DV27.1, DV28.1, DV29.1, MR30.0, MR30.1; Nuclear Magnetic Resonance Imaging System

    U.S. Food and Drug Administration - Published 2024-08-02 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  8. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  9. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  10. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  11. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  12. GE HealthCare AIR Recon DL

    GE HealthCare - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  13. SIGNA Artist 1.5T wide-bore MRI system

    GE HealthCare - Accessed 2026-09-03

    Scope: productFamily, workflowRole, implementationCapabilities, currentCommercialContext

Research history

  1. K202238 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K252838

MAGNETOM Sola; MAGNETOM Altea; MAGNETOM Sola Fit; MAGNETOM Viato.Mobile; MAGNETOM Vida; MAGNETOM Lumina; MAGNETOM Vida Fit; MAGNETOM Flow.Elite; MAGNETOM Flow.Neo; MAGNETOM Flow.Rise

Siemens Healthcare GmbH

Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history